|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Mycoplasma infections and different human carcinomas显示文摘AIM To explore relationships between human carcinomas and mycoplasma infection.METHODS Monoclonal antibody PD4, which specifically recognizes a distinct protein from mycoplasma hyorhinis, was used to detect mycoplasma infection in different paraffinembedded carcinoma tissues with immunohistochemistry. PCR was applied to amplify the mycoplasma DNA from the positive samples for confirming immunohistochemistry.RESULTS Fifty of 90 cases (56%) of gastric carcinoma were positive for mycoplasma hyorhinis. In other gastric diseases, the mycoplasma infection ratio was 28% (18/49) in chronic superficial gastritis, 30% (14/ 46) in gastric ulcer and 37% (18/ 49) in intestinal metaplasia. The difference is significant with gastric cancer (X2=12.06, P<0.05). In colon carcinoma, the mycoplasma infection ratio was 55.1% (32/58), but it was 20.9% (10/49) in adenomarous polyp (X2=13.46, P<0.005).Gastric and colon cancers with high differentiation had a higher mycoplasma infection ratio than those with low differentiation (P< 0.05). Mycoplasma infection in esophageal cancer, lung cancer, breast cancer and glioma was 50.9% (27/53), 52.6% (31/ 59), 39.7%(25/63) and 41% (38/91), respectively. The mycoplasma DNA was successfully amplified with the DNA extracted from the cancer tissues that were positive for mycoplasma infection (detected with antibody PD4).CONCLUSION There was high correlation between mycoplasma infection and different cancers, which suggests the possibility of an association between the two. The mechanism involved in oncogenesis by mycoplasma remains unknown. | Su Huang Ji You Li Jan Wu Lin Meng Cheng Chao Shou Beijing Institute for Cancer Research, Peking University School of Oncology, Beijing 100034. ChinaSu Huang, received B. A from Jiangxi Medical College of China in 1994. Now she is a graduate student pursuing a Ph. D degree at the Peking University School of Oncology. | 2001 | World Journal of Gastroenterology2001，7，2： | 18 |
| 2 | Clostridium difficile infections in China显示文摘Clostridium difficile (C. difficile) infection has become one of the major hospital-associated infections in West-ern countries in the last two decades. However, there is limited information on the status of C. difficile infection inChinese healthcare settings. Given the large and increasing elderly population and the well-recognized problem ofover-prescribing of broad spectrum antibiotics in China, it is critical to understand the epidemiology and potentialrisk factors that may contribute to C. difficile infection in China. A literature review of available published studies,including those in Chinese language-based journals, was conducted. A review of the currently available literaturesuggested the presence of C. difficile infections in China, but also suggested that these infections were not particu-larly endemic. This finding should lead to better designed and greatly expanded studies to provide a more reliableepidemiologically-based conclusion on the actual status of C. difficile infection in China, including the identifica-tion of any associated risk factors. Such information is ultimately valuable to develop appropriate strategies to pre-vent C. difficile infection and the vast negative impact of such infections in China and other developing countries. | Ke Jin a,b,c,Shixia Wang c,d,Zuhu Huang a,b,c,Shan Lu b,c,daDepartment of Infectious Diseases,bJiangsu Province Key Laboratory in Infectious Diseases,cChina-US Vaccine ResearchCenter,the First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210029,China d Department of Medicine,University of Massachusetts Medical School,Worcester,MA 01655,USA. | 2010 | The Journal of Biomedical Research2010，24，6： | 14 |
| 3 | Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review显示文摘AIM: To identify severe adverse events (SAEs) leading to treatment discontinuation that occur during antiviral therapy in hepatitis C virus (HCV)-infected cirrhotic patients. METHODS: We identified all the articles published prior to December 2011 in the PubMed, Medline, Lilacs, Scopus, Ovid, EMBASE, Cochrane and Medscape databases that presented these data in cirrhotic patients. These studies evaluated the rate of SAEs leading to discontinuation of standard care treatment: Pegylated interferon (PegIFN) alpha 2a (135-180 μg/wk) or PegIFN alpha 2b (1 or 1.5 μg/kg per week) and ribavirin (800-1200 mg/d). Patients with genotype 1 + 4 underwent treatment for 48 wk, whereas those with genotypes 2 + 3 were treated for 24 wk.RESULTS: We included 17 papers in this review, comprising of 1133 patients. Treatment was discontinued due to SAEs in 14.5% of the patients. The most common SAEs were: severe thrombocytopenia and/or neutropenia (23.2%), psychiatric disorders (15.5%), decompensation of liver cirrhosis (12.1%) and severe anemia (11.2%). The proportion of patients who needed to discontinue their therapy due to SAEs was significantly higher in patients with Child-Pugh class B and Cvs those with Child-Pugh class A: 22%vs 11.4% (P = 0.003). A similar discontinuation rate was found in cirrhotic patients treated with PegIFN alpha 2a and those treated with PegIFN alpha 2b, in combination with ribavirin: 14.2%vs 13.7% (P = 0.96). The overall sustained virological response rate in cirrhotic patients was 37% (95%CI: 33.5-43.1) but was significantly lower in patients with genotype 1 + 4 than in those with genotype 2 + 3: 20.5% (95%CI: 17.9-24.8) vs 56.5% (95%CI: 51.5-63.2), (P < 0.0001). CONCLUSION: Fourteen point five percent of HCV cirrhotic patients treated with PegIFN and ribavirin needed early discontinuation of therapy due to SAEs, the most common cause being hematological disorders. | Simona Bota Ioan Sporea Roxana Sirli Alina Popescu Adriana Maria Neghinǎ Mirela Dǎnilǎ Mihnea Strǎin | 2013 | World Journal of Hepatology2013，5，3： | 6 |
| 4 | Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial显示文摘 | Wendy S Atkin Rob Edwards Ines Kralj-Hans Kate Wooldrage Andrew R Hart John MA Northover D Max Parkin Jane Wardle Stephen W Duffy Jack Cuzick | 2010 | The Lancet2010，，9726： | 4 |
| 5 | Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy?显示文摘AIM: To define the (co-)expression pattern of target receptor-tyrosine-kinases (RTK) in human gastric adenocarcinoma. METHODS: The (co-)expression pattern of VEGFR1-3,PDGFRα/b and EGFR1 was analyzed by RT-PCR in 51 human gastric adenocarcinomas. In addition,IHC staining was applied for confirmation of expression and analysis of RTK localisation. RESULTS: The majority of samples revealed a VEGFR1 (98%),VEGFR2 (80%),VEGFR3 (67%),PDGFRα (82%) and PDGFRβ(82%) expression,whereas only 62% exhibited an EGFR1 expression. 78% of cancers expressed at least four out of six RTKs. While VEGFR1-3 and PDGFRα revealed a predominantly cytoplasmatic staining in tumor cells,accompanied by an additional nuclear staining for VEGFR3 ,EGFR1 was almost exclusively detected on the membrane of tumor cells. PDGFRβ was restricted to stromal pericytes,which also depicted a PDGFRα expression.receptor-tyrosine-kinases coexpression in gastric adenocarcinoma and might therefore encourage an application of multiple-target RTK-inhibitors within a combination therapy. | Daniel Drescher Markus Moehler Ines Gockel Kirsten Frerichs Annett Müller Friedrich Dünschede Thomas Borschitz Stefan Biesterfeld Martin Holtmann Thomas Wehler Andreas Teufel Kerstin Herzer Thomas Fischer Martin R Berger Theodor Junginger Peter R Galle Carl C Schimanski | 2007 | World Journal of Gastroenterology2007，13，26： | 4 |
| 6 | Agent-oriented Aid-modeling for the Distributed Activity Network | DENG Gui\|shi\+1,\ LI Wen\|lei\+1,\ O. Moeschlin\+2 1.Institute of Systems Engineering, Dalian University of Technology Dalian 116024, China 2.Department of Mathematics, Fern University in Hagen, D 58084 Germany | 2000 | Systems Science and Systems Engineering2000，10，1： | 4 |
| 7 | Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial显示文摘 | Wendy S Atkin Rob Edwards Ines Kralj-Hans Kate Wooldrage Andrew R Hart John MA Northover D Max Parkin Jane Wardle Stephen W Duffy Jack Cuzick | 2010 | 2010 (9726)2010，，9726： | 3 |
| 8 | Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinoma显示文摘AIM: To evaluate the efficacy and the safety of azathioprine (AZA) and buthionine sulfoximine (BSO) bylocalized application into HepG2 tumor in vivo.METHODS: Different hepatoma and colon carcinoma cell lines (HepG2, HuH7, Chang liver, LoVo, RKO, SW-48, SW-480) were grown in minimal essencial medium supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic solution and maintained in a humidified 37 ℃ incubator with 5% CO2. These cells were pretreated with BSO for 24 h and then with AZA for different times. We examined the effects of this combination on some proteins and on cellular death. We also studied the eff icacy and the safety of AZA (6 mg/kg per day) and BSO (90 mg/kg per day) in HepG2 tumor growth in vivo using athymic mice. We measured safety by serological markers such as aminotransferases and creatine kinase.RESULTS: The in vitro studies revealed a new mechanism of action for the AZA plus BSO combination in the cancer cells compared with other thiopurines (6-mercaptopurine, 6-methylmercaptopurine, 6-thioguanine and 6-methylthioguanine) in combination with BSO. The cytotoxic effect of AZA plus BSO in HepG2 cells resulted from necroptosis induction in a mitochondrial-dependent manner. From kinetic studies we suggest that glutathione (GSH) depletion stimulates c-Jun amino-terminal kinase and Bax translocation in HepG2 cells with subsequent deregulation of mitochondria (cytochrome c release, loss of membrane potential), and proteolysis activation leading to loss of membrane integrity, release of lactate dehydrogenase and DNA degradation. Some of this biochemical and cellular changes could be reversed by N-acetylcysteine (a GSH replenisher). In vivo studies showed that HepG2 tumor growth was inhibited when AZA was combined with BSO.CONCLUSION: Our studies suggest that a combination of AZA plus BSO could be useful for localizedtreatment of hepatocellular carcinoma as in the currently used transarterial chemoembolization method. | Borja Hernández-Breijo Jorge Monserrat Sara Ramírez-Rubio Eva P Cuevas Diana Vara Inés Díaz-Laviada M Dolores Fernández-Moreno Irene D Román Javier P Gisbert Luis G Guijarro | 2011 | World Journal of Gastroenterology2011，17，34： | 2 |
| 9 | Impact of mobile health and medical applications on clinical practice in gastroenterology显示文摘Mobile health apps (MHAs) and medical apps (MAs) are becoming increasinglypopular as digital interventions in a wide range of health-related applications inalmost all sectors of healthcare. The surge in demand for digital medical solutionshas been accelerated by the need for new diagnostic and therapeutic methods inthe current coronavirus disease 2019 pandemic. This also applies to clinicalpractice in gastroenterology, which has, in many respects, undergone a recentdigital transformation with numerous consequences that will impact patients andhealth care professionals in the near future. MHAs and MAs are considered tohave great potential, especially for chronic diseases, as they can support the selfmanagementof patients in many ways. Despite the great potential associated withthe application of MHAs and MAs in gastroenterology and health care in general,there are numerous challenges to be met in the future, including both the ethicaland legal aspects of applying this technology. The aim of this article is to providean overview of the current status of MHA and MA use in the field ofgastroenterology, describe the future perspectives in this field and point out someof the challenges that need to be addressed. | Sven Kernebeck Theresa S Busse Maximilian D Bottcher Jurgen Weitz Jan Ehlers Ulrich Bork Didactics Educational Research in Health | 2020 | World Journal of Gastroenterology2020，26，29： | 2 |
| 10 | Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial显示文摘 | Wendy S Atkin Rob Edwards Ines Kralj-Hans Kate Wooldrage Andrew R Hart John MA Northover D Max Parkin Jane Wardle Stephen W Duffy Jack Cuzick | 2010 | The Lancet . 2010 (9726)2010，，： | 2 |
| 11 | Review of cases reported over the past twenty -five years 显示文摘 | Miguel G madariaga NG Sandra D polymyositis - like syn- drome in hypothyroidism | 2002 | Thyroid2002，12，： | 1 |
| 12 | Synthesis of 3,5-diamino-1 , 2,4-triazole 显示文摘 | Chernyshev V M Zemlyakov N D Il'in V B | 2000 | Prikl Khim2000，73，79： | 1 |
| 13 | Intensive Immunosuppression with antithymocyte globulin and cyclospo-rine as treatment for severe aplastic anemia显示文摘 | Ro senfeld SJ Kimball JK V ining D | 1995 | Blood1995，85，11： | 1 |
| 14 | 3D confomal al- HDR- brachy and external beam therapy plus sinultaneous cisp latin for high - risk cervical cancer clinical experience with 3 year follow up显示文摘 | PotterR D in opou los J Bachtiary B | 2006 | Radiother Oncol2006，79，1： | 1 |
| 15 | Hand-assisted laparoscopic surgery(HALS) with the handport system 显示文摘 | Liw in D Darzi A Jakinowicz J | 2000 | Ann Surg2000，231，5： | 1 |
| 16 | Posterior reversibleencephalopathy syndrome (PRES):Features on CT and MRimaging显示文摘 | Hugonnet E Da Ines D Boby H | 2012 | Diagn Interv Imaging2012，94，1： | 1 |
| 17 | The role of angular momentum compensation显示文摘 | Stanciu C D Kimel A V Hansteen F et aL Ultrafast spin dynamics across compensation points in ferrimagnetic GdFeCo | 2006 | Phys Rev B2006，73，22： | 1 |
| 18 | A controlled trial 显示文摘 | Kleinknecht D Ganeval D Gonzalez-Duque LA Furo-semide in acute oliguric renal failure | 1976 | Nephron1976，17，1： | 1 |
| 19 | Construction of large signaling pathways using an adaptive perturbation approach with phosphoproteomic data显示文摘 | Melas IN Mitsos A Messinis D | 2012 | Mol Biosyst2012，8，5： | 1 |
| 20 | Prevalence of over- weight an d obesity in the United States, 1999 - 2004 显示文摘 | OGDEN CL CARROLL M D CU RT IN LR | 2006 | JAMA2006，29，13： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员